NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
InflaRx N.v. IFRX
11 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
€29,331
▼ 82.3% vs FY2024
EPS · FY25
€-0.68
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-624.6%
Net margin · FY25
-155582.1%
Dividend coverage
-0.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 29,331.00
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 155582 cents on every revenue dollar this year.
Per share
EUR -0.68
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-624.6%
Return on equity, FY2025
ROE
Operating margin—
Net margin-155582.1%
Return on assets-69.5%
Each EUR of equity lost 625 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 55.2M
total assets, end of FY2025
Total assetsEUR 55.2M
EquityEUR 7.2M
CashEUR 16.0M
Current ratio4.13×
Equity funds 13% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue €B
0.0
0.0
0.0
·
·
·
·
·
·
·
·
Operating income €B
·
·
−0.0
−0.0
−0.0
·
·
·
·
·
·
EBITDA €B
·
·
−0.0
−0.0
−0.0
·
·
·
·
·
·
Income tax €B
0.0
0.0
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income €B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted €
−0.68
−0.78
−0.78
−0.67
−1.10
−1.26
·
−1.19
−2.60
−3.80
·
Dividend / sh €
·
·
5.00
5.00
·
·
·
·
·
·
·
Payout %
·
·
−5
−254
·
·
·
·
·
·
·
ROE %
−624.6
−621.5
−582.9
−572.1
−1495.9
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
32 of 32
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed